Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01412918 · ClinicalTrials.gov registry record · NA
Inhibitor Masking Device & Sodium Channel, Voltage Gated, Type IX Alpha Subunit (SCN9) Gene Expression
A NA study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT01412918 is a NA study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 21 participants.
The verdict
NCT01412918, a NA study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
To evaluate the effectiveness of the Inhibitor™ Tinnitus Masking Device. To determine if there is a higher incident of expression of the sodium channel, voltage gated, type IX alpha subunit (SCN9) gene in those subjects with disturbing tinnitus than subjects that are not disturbed by tinnitus.
Interventions
- DEVICE The Inhibitor™ Tinnitus Masking Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-09 |
| Est. Completion | 2014-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01412918
The ClinicalTrials.gov registry entry for NCT01412918 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which The Inhibitor™ Tinnitus Masking Device is the first listed.
NCT01412918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01412918 about?
NCT01412918 is a clinical study titled "Inhibitor Masking Device & Sodium Channel, Voltage Gated, Type IX Alpha Subunit (SCN9) Gene Expression". To evaluate the effectiveness of the Inhibitor™ Tinnitus Masking Device. To determine if there is a higher incident of expression of the sodium channel, voltage gated, type IX alpha subunit (SCN9) gene in those subjects with disturbing tinnitus than subjects that are not disturbed by tinnitus.
What is the current status of trial NCT01412918?
This trial is currently terminated. It is a NA study. The enrollment target is 21 participants. The study started on 2011-09. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01412918?
The interventions under investigation include: The Inhibitor™ Tinnitus Masking Device (DEVICE).
Who is sponsoring clinical trial NCT01412918?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.